Company founded: August 2013
CALCISCO develops and commercializes the very first and only diagnostic blood test available for the determination of calcification risk/propensity in serum (Pasch et al., JASN, 2012; “T50 test”). The main product will be a diagnostic test kit sold and distributed to clinical laboratories. The first target group to benefit from the T50 test is chronic kidney disease (CKD) patients.
A research test service is already established and currently offered mainly for clinical studies; the diagnostic test kit will follow.
In the long-term, extension to the general cardiovascular field is envisaged, and novel treatment options to reduce calcification risk shall be developed.
Milestones / News
Videos and Presentations
|Share this profile with others|